At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 126 enrolled
Drug / intervention
LIK066 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 12 Weeks Treatment With 4 Doses of LIK066 Compared to Placebo in Japanese Patients With Obesity Disease
In Brief
A Phase 2 clinical trial evaluating LIK066 and Placebo for Obesity. Completed, enrolled 126 participants across 24 sites.
Detailed Summary
The purpose of the study is to evaluate the efficacy, tolerability and safety of LIK066 to support dose selection for Phase 3 development in Japanese adults with obesity disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartDec 2017
Primary CompletionJul 2018
TodayJul 2026
First PostedOct 25, 2017
Enrollment StartDec 7, 2017
Primary CompletionJul 25, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.7 years ago
Interventions
LIK066drug
LIK066 will be supplied in different doses as tablets to be taken orally daily.
Placebodrug
Placebo will be supplied as tablets to be taken daily orally.